Proactive Investors - Run By Investors For Investors

Imugene rings in changes as gastric cancer trial preparation picks up pace

Imugene rings in changes as gastric cancer trial preparation picks up pace

Imugene (ASX:IMU) has added Dr. Anton Uvarov to its Board as a non executive director as the immuno-oncology company picks up the pace of work for its gastric cancer study in 2016.

Dr Uvarov worked for two years in the U.S. healthcare research team at Citigroup Global Markets covering small and mid-cap biotechnology companies and holds a PhD degree in Biochemistry and Medical Genetics.

Stuart Roberts was appointed Head of Corporate Development this week. Previously he worked at Prima BioMed (ASX:PRR).

Imugene is a clinical stage immuno-oncology company with a lead product, HER-Vaxx a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

Immuno-oncology is a relatively new but highly promising field that uses the method of activating a patient's immune system against tumour growth.

Imugene's unique immunotherapy has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a known and validated cancer target.

HER-Vaxx’s successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer.

Novotech was recently appointed as the lead contract researcher for the upcoming Phase 1b/2 trial of HER-Vaxx in gastric cancer.

The trial design was largely completed with a focus on Asia. Start up activity for the HER-Vaxx Phase 1b/2 study in gastric cancer is underway and clinical commencement is expected in the first half of 2016.

Under Novotech, Imugene’s investigators will recruit patients with HER-2 positive gastric cancer at a number of leading cancer centres in Asia.

The study will be conducted in two parts. The initial Phase 1b will be an open-label dose escalation study designed to evaluate the safety as well as the pharmacokinetics of HER-Vaxx. This will also determine optimal dosage.

A larger Phase 2 study will be a randomised controlled study of HER-Vaxx plus standard of care against standard of care alone.

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

View full IMU profile View Profile

Imugene Ltd Timeline

September 07 2015

Related Articles

Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
January 03 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use